Medical Weight Loss in Fargo, ND: Physician-Prescribed GLP-1 Medications, Semaglutide and Tirzepatide
Aly Dahl, PA-C is a passionate advocate for obesity medicine and leads the GLP-1 program alongside Dr. Kristine Martens, DO. Aly earned her Master of Physician Assistant Studies from the University of North Dakota and has practiced Family Medicine in Fargo since 2017. Her approach to medical weight loss is grounded in transparent pricing, brand-name FDA-approved medications, and monthly follow-up visits, no rushed refills.
Table of Contents
When Diet Alone Falls Short and Medical Weight Loss Helps
Understanding Metabolic Resistance
For many patients, weight is not a willpower problem. You may have followed sensible eating, walked most days, and still watched the scale stall or slowly climb. Constant hunger, food noise between meals, and post-meal blood sugar swings make consistency almost impossible. Genetics, hormonal shifts, thyroid patterns, sleep debt, and years of dieting all reshape your metabolism. By the time you reach us, you are often frustrated, tired of gimmicky programs, and skeptical that anything else will actually work long term.
GLP-1 medications like semaglutide (Wegovy) and tirzepatide (Zepbound) work with your biology, not against it. They mimic hormones your gut already makes to slow digestion, reduce hunger, and steady blood sugar. Combined with our monthly visits, baseline labs, and personalized nutrition and strength recommendations, most patients see steady, sustainable loss over six to twelve months. We do not chase quick numbers. We build a plan around your health history, tolerance, and goals so results last after the medication stops.
What Is Medical Weight Loss And How It Works
Medical weight loss at Resurgent Health uses self-administered, once-weekly GLP-1 receptor agonists. The FDA-approved options for chronic weight management are Wegovy (semaglutide) and Zepbound (tirzepatide); Ozempic and Mounjaro share the same active ingredients but are approved for type 2 diabetes and used off-label when clinically appropriate.
GLP-1 is a gut hormone that prompts insulin release, slows stomach emptying, and signals fullness to the brain; tirzepatide adds GIP activity, which is why many patients lose slightly more on it. In pivotal trials summarized by the NIDDK, semaglutide averaged about 15% body-weight loss and tirzepatide about 21%. The medication is self-administered once weekly with a short, thin pre-filled pen in the abdomen, thigh, or arm; appetite drops in the first week and full effect builds over six to twelve months.
Treatment Timeline:
First Signs:
1 - 2 weeks (appetite and cravings drop)
Full Effect:
6 - 12 months (peak, steady weight loss)
Treatment Time:
Weekly (self-administered at home)
Recovery:
None (no downtime between doses)
Medical Weight Loss Treatment Areas
Benefits of Medical Weight Loss
Achieve lasting weight loss with physician-guided treatment that helps control hunger, improve metabolic health, and support long-term success
Appetite
Suppresses appetite and curbs cravings
Benefits
Supports sustainable, long-term fat loss
Brand-Name
Boosts long-term metabolic health
Support
Behavior, nutrition & lab support
Weekly Convenience
One weekly dose with a pre-filled pen
Medical Weight Loss vs. Alternatives
Compare Your Options
| Treatment | Mechanism | Time | Results | Duration | Downtime | Best For |
|---|---|---|---|---|---|---|
| Medical Weight Loss (GLP-1) | Appetite and insulin regulation | Weekly dose | 15-21% body weight loss | 6-12 months and beyond | None | BMI 30+ or 27+ with comorbidity |
| Bariatric Surgery | Stomach anatomy change | One-time procedure | 25-35% body weight loss | Long-term with lifestyle | 2-6 weeks | BMI 35+ with severe comorbidity |
| Commercial Weight-Loss Programs | Diet and behavior coaching | Weekly meetings | 3-8% body weight loss | During active program | None | Motivated dieters, mild excess weight |
| Compounded GLP-1s | Unregulated peptide | Weekly dose | Variable, unverified | Unclear | None | Not recommended, safety unknown |
Who Is a Good Candidate for Medical Weight Loss?
Most of our GLP-1 program patients are adults who have tried diet and exercise on their own and are ready for a medically supervised next step. The FDA recommends brand-name GLP-1 medications for chronic weight management within specific BMI criteria.
Ideal Candidates for Medical Weight Loss
- Adults with a BMI of 30 or higher
- BMI of 27 or higher with a weight-related condition like type 2 diabetes
- Patients who tried diet and lifestyle change without lasting results
Who Should Wait or Avoid GLP-1 Medication
- Personal or family history of medullary thyroid carcinoma or MEN2
- Pregnancy, planning pregnancy, or currently breastfeeding
- History of pancreatitis, severe gastroparesis, or drug hypersensitivity
Honest Expectations About Results
- Supports appetite control, working alongside nutrition and activity
- Most lose weight gradually over months as the dose is adjusted
- Weight can return without lasting lifestyle change, so we plan long-term
Absolute contraindications are non-negotiable for your safety. Aly will review your full history and order baseline lab work before prescribing to make sure this program is right for you.
What Happens During Medical Weight Loss Treatment
Step-by-Step Process
Consult and Eligibility
Labs and Baseline
Prescription and Pen Training
Monthly Follow-Up
Titration and Dose Adjustments
Risks and Side Effects
What to Know
Common Medical Weight Loss Side Effects
Nausea (about 20 to 44 percent of patients), constipation, diarrhea, mild abdominal discomfort, fatigue, and injection-site reactions are the most common. These are usually mild to moderate and typically resolve within two to six weeks as your body adjusts, or after a slow dose titration.
Rare Complications
Pancreatitis (roughly 0.1 to 0.2 percent), gallbladder disease, severe gastroparesis, kidney injury from dehydration, and rare allergic reactions have been reported. GLP-1 medications carry a boxed warning about thyroid C-cell tumors seen in rodent studies, which is why personal or family history of medullary thyroid carcinoma or MEN2 is an absolute contraindication.
Safety and FDA Status
Wegovy (semaglutide) was FDA-approved for chronic weight management in 2021, and Zepbound (tirzepatide) was FDA-approved in 2023. Both are brand-name, tightly regulated, and dispensed as pre-filled pens with verified potency. We do not prescribe compounded or gray-market semaglutide because purity, dosing, and long-term safety are not verified. The Obesity Medicine Association publishes clinical guidelines that shape how Aly manages titration, monitoring, and long-term dosing at Resurgent Health.
Medical Weight Loss Cost in Fargo
Pricing and Payment Options
The Resurgent Health medical weight loss program has a transparent monthly clinical fee that covers your consult, baseline labs review, monthly follow-ups, and nutrition and behavior coaching. Exact program pricing will be reviewed at your first visit so there are no surprises. Medication cost is separate and varies based on insurance coverage, cash-pay pharmacy pricing, and manufacturer savings cards. We are happy to help you check medical weight loss coverage before you commit.
Medication Pricing Notes
- With insurance coverage - Copays for Wegovy and Zepbound vary widely. Many patients pay 30 to 100 dollars per month with a covered plan and a manufacturer savings card.
- Cash-pay pricing - Full retail pricing for brand-name Wegovy and Zepbound typically runs 1,000 to 1,350 dollars per month at large pharmacies before any discounts.
- Manufacturer savings programs - Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) both offer patient savings programs that we can help you enroll in.
Flexible Payment Options
We do not push financing, but we can point you toward common options if the medication cost is a stretch:
- Manufacturer savings cards - Direct discounts from Novo Nordisk and Eli Lilly for eligible patients.
- HSA and FSA accounts - GLP-1 medication prescribed for a qualifying condition is typically eligible.
Why Choose Resurgent Health for Medical Weight Loss in Fargo
Aly Dahl, PA-C is a passionate advocate for obesity medicine and has practiced Family Medicine in Fargo since 2017. Together with Dr. Kristine Martens, DO, she designs a full medical program around each patient: thyroid and A1C screening, baseline labs, monthly follow-ups, and honest behavior and nutrition coaching, not a refill mill.
Full Medical Workup
Thyroid, A1C, and baseline labs before your first dose, not after
Brand-Name Medications
Only FDA-approved Wegovy and Zepbound, no compounded semaglutide
Monthly Follow-Ups
Consistent visits to manage side effects and adjust your dose
Real Lifestyle Support
Nutrition, strength, and sleep coaching built into every visit
Never Compounded
Only FDA-approved Wegovy and Zepbound, never unregulated gray-market peptides
Savings Program Support
Help enrolling in manufacturer savings cards to make brand-name medication more affordable
Related Services in Fargo, ND
Complement your GLP-1 program with these treatments.
In-Office Procedures
Minor procedures performed in-clinic during your DPC visit, with supplies at wholesale cost and no separate copay.
- DPC members with a minor skin, joint, ear, or surgical concern
- Patients who want continuity with their own primary care doctor
- Generally stable health with no active infection at the site
Lab Work & Blood Tests
Comprehensive lab panels at direct-to-patient wholesale pricing for DPC members.
- Adults establishing baseline preventive screening (CBC, CMP, lipid, A1C)
- Members monitoring diabetes, thyroid disease, or high cholesterol
- Patients frustrated by unpredictable lab bills or high deductibles
Therapeutic Injections
Vitamin and anti-inflammatory injections at wholesale cost
- Active DPC members with a confirmed B12 or vitamin D deficiency
- Patients with a localized joint flare, trigger point, or trigger finger
- Members needing short-term relief while pursuing longer-term care
Frequently Asked Questions About Medical Weight Loss
How much weight will I lose on GLP-1 medication?
In clinical trials, semaglutide averaged about 14.9% body weight loss and tirzepatide about 20.9% over roughly 15 to 17 months. Real-world results vary based on dose, adherence, and lifestyle support.
Does the weekly pen hurt?
Most patients say the weekly pen is easier than a flu shot. The needle is very short and thin. Aly walks you through the technique at your kickoff visit until you feel confident.
Can I combine medical weight loss with other services?
Yes. Many patients pair the medication with core strengthening on Emsculpt Neo to preserve and build lean muscle, plus routine lab work to track metabolic markers over time.
How do I keep the weight off after stopping?
Most patients need ongoing lifestyle work, and some choose long-term maintenance dosing. Aly will help you build a taper and maintenance plan that fits your goals and biology.
Do you prescribe compounded semaglutide?
No. We only prescribe brand-name, FDA-approved Wegovy and Zepbound. Compounded semaglutide has unclear purity and safety, and the FDA has issued warnings about several unapproved versions.
Is it covered by insurance?
Coverage varies widely by plan and employer. We will help you check your benefits and use manufacturer savings cards to lower cost when your plan does not cover it.
Am I a good candidate?
The FDA criteria are a BMI of 30 or higher, or 27 or higher with a weight-related condition like type 2 diabetes, hypertension, or sleep apnea. Aly confirms candidacy at your first visit.
Contact Us Today
Send us a message for more information - DPC membership, a discovery call, or any other service you'd like to ask about.
References
- PubMed (PMID: 33567185) - Wilding JPH et al. (STEP 1) reported an average 14.9% body weight reduction with once-weekly semaglutide 2.4 mg over 68 weeks in adults with overweight or obesity.
- PubMed (PMID: 35658024) - Jastreboff AM et al. (SURMOUNT-1) demonstrated up to 20.9% average body weight loss with tirzepatide 15 mg over 72 weeks in adults with obesity.
- PubMed (PMID: 31767182) - Muller TD et al. Glucagon-like peptide 1 (GLP-1). Mol Metab, 2019: comprehensive review of GLP-1 physiology, appetite regulation, insulin secretion, and glucose homeostasis.
- FDA - FDA approval of Wegovy (semaglutide) for chronic weight management in adults, 2021.
- Obesity Medicine Association - Clinical practice guidelines on obesity pharmacotherapy, including GLP-1 receptor agonists.